Vaccines for melanoma.
Melanoma vaccines are now an accepted but still experimental treatment for patients who have been rendered clinically free of disease by surgical resection but are at high risk of recurrence and in selected patients with advanced but still limited disease. In general, there seems to be a correlation between the ability of melanoma vaccines to stimulate antimelanoma cellular or antibody immune responses and improved clinical outcome. Accordingly, a number of strategies are now being pursued to improve the clinical effectiveness of this first generation of vaccines by improving their ability to stimulate antimelanoma immunity. To establish the true effectiveness of vaccines in the treatment of malignant melanoma, several large, prospectively randomized phase III studies are currently being conducted.
Bystryn
Jean-Claude
JC
Ronald O. Perelman Department of Dermatology and Melanoma Program, Melanoma Immunotherapy Clinic, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 35 East 35th Street, Suite 208, New York, NY 10016, USA. bystryn@nyu.edu
D001707:Biopsy, Needle; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D019496:Cancer Vaccines